Anti-PD-1 and anti-PD-l1 antibodies as immunotherapy against cancer: a structural perspective
Rev. invest. clín; 73 (1), 2021
ABSTRACT Programmed cell death protein 1 (PD-1) and its ligand, programmed death-ligand-1 (PD-L1), play key roles in the suppression of the cytotoxic activity of T cells. PD-L1 is overexpressed on various types of cancer cells, leading to immune evasion. In the past decade, therapeutic antibodies that ta...